Titre:
  • Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Auteur:Baselga, José; Campone, Mario; Piccart-Gebhart, Martine; Burris, Howard A; Rugo, Hope; Sahmoud, Tarek; Noguchi, S; Gnant, Michael; Pritchard, Kathleen; Lebrun, Fabienne; Beck, J Thaddeus; Ito, Y; Yardley, Denise A; Deleu, I; Perez, Alejandra; Bachelot, Thomas; Vittori, Luc; Xu, Z.; Mukhopadhyay, Pabak; Lebwohl, David; Hortobagyi, Gabriel N.
Informations sur la publication:The New England journal of medicine, 366, 6, page (520-529)
Statut de publication:Publié, 2012-02
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Aged, 80 and over
Androstadienes -- adverse effects -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Aromatase Inhibitors -- adverse effects -- therapeutic use
Bone Neoplasms -- secondary
Breast Neoplasms -- chemistry -- drug therapy
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Postmenopause
Receptor, Epidermal Growth Factor -- analysis
Recurrence
Sirolimus -- adverse effects -- analogs & derivatives -- therapeutic use
Stomatitis -- chemically induced
TOR Serine-Threonine Kinases -- antagonists & inhibitors
Note générale:Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0028-4793
info:doi/10.1056/NEJMoa1109653
info:scp/84863078767
info:pmid/22149876